Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

INSIDE BLOOD ADVANCES

DRUG ADVANCES

REVIEW ARTICLES

CLINICAL TRIALS AND OBSERVATIONS

An updated risk-oriented strategy resulting in 3-year OS and DFS rates >60% in adult patients 18-65 years with Ph-negative ALL

HEALTH SERVICES AND OUTCOMES

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

RESEARCH LETTERS

COMMENTARIES

ERRATA

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals